Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label rusfertide trial in Japanese patients with polycythemia vera
jRCT2031260215Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rusfertide in polycythemia vera (PV), sponsored by Takeda. Primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 through Week 32. Started Jul 2026; status: recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT2031260215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260215.